62 related articles for article (PubMed ID: 18617357)
1. Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
Kaneko M; Kaneko S; Suzuki K
Cancer Sci; 2009 Nov; 100(11):2193-201. PubMed ID: 19673886
[TBL] [Abstract][Full Text] [Related]
2. The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma.
Hillion J; Smail SS; Di Cello F; Belton A; Shah SN; Huso T; Schuldenfrei A; Nelson DM; Cope L; Campbell N; Karikari C; Aderinto A; Maitra A; Huso DL; Resar LM
Pancreatology; 2012; 12(4):372-9. PubMed ID: 22898640
[TBL] [Abstract][Full Text] [Related]
3. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
Bernard MP; Bancos S; Sime PJ; Phipps RP
Curr Pharm Des; 2008; 14(21):2051-60. PubMed ID: 18691115
[TBL] [Abstract][Full Text] [Related]
4. COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers.
Rodrigues P; Bangali H; Hammoud A; Mustafa YF; Al-Hetty HRAK; Alkhafaji AT; Deorari MM; Al-Taee MM; Zabibah RS; Alsalamy A
Med Oncol; 2024 Jan; 41(1):41. PubMed ID: 38165473
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of guttiferone E in melanoma-bearing mice.
Ribeiro AB; de Melo MRS; de Melo Junqueira M; Rodrigues MGL; de Souza TO; Fernandes G; Santos MFC; Ambrósio SR; Bastos JK; Tavares DC
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; ():. PubMed ID: 38270618
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors.
Wang S; Wang C; Wang X; Wang X; Huang L; Kuai J; Wei W; Lu X; Yan S
Cancer Chemother Pharmacol; 2021 Nov; 88(5):795-804. PubMed ID: 34309733
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies in bladder cancer: an overview of in vivo research.
van Kessel KE; Zuiverloon TC; Alberts AR; Boormans JL; Zwarthoff EC
Nat Rev Urol; 2015 Dec; 12(12):681-94. PubMed ID: 26390971
[TBL] [Abstract][Full Text] [Related]
8. A multi-targeted approach to suppress tumor-promoting inflammation.
Samadi AK; Bilsland A; Georgakilas AG; Amedei A; Amin A; Bishayee A; Azmi AS; Lokeshwar BL; Grue B; Panis C; Boosani CS; Poudyal D; Stafforini DM; Bhakta D; Niccolai E; Guha G; Vasantha Rupasinghe HP; Fujii H; Honoki K; Mehta K; Aquilano K; Lowe L; Hofseth LJ; Ricciardiello L; Ciriolo MR; Singh N; Whelan RL; Chaturvedi R; Ashraf SS; Shantha Kumara HMC; Nowsheen S; Mohammed SI; Keith WN; Helferich WG; Yang X
Semin Cancer Biol; 2015 Dec; 35 Suppl():S151-S184. PubMed ID: 25951989
[TBL] [Abstract][Full Text] [Related]
9. Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression.
Zuo W; Wang ZZ; Xue J
Int J Mol Sci; 2014 Aug; 15(8):14298-312. PubMed ID: 25196524
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells.
Huang KH; Kuo KL; Ho IL; Chang HC; Chuang YT; Lin WC; Lee PY; Chang SC; Chiang CK; Pu YS; Chou CT; Hsu CH; Liu SH
PLoS One; 2013; 8(12):e82034. PubMed ID: 24349176
[TBL] [Abstract][Full Text] [Related]
11. The effects of piroxicam and deracoxib on canine mammary tumour cell line.
Ustün Alkan F; Ustüner O; Bakırel T; Cınar S; Erten G; Deniz G
ScientificWorldJournal; 2012; 2012():976740. PubMed ID: 23251109
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells.
Huang KH; Kuo KL; Chen SC; Weng TI; Chuang YT; Tsai YC; Pu YS; Chiang CK; Liu SH
PLoS One; 2012; 7(3):e33615. PubMed ID: 22438966
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines.
Adhim Z; Matsuoka T; Bito T; Shigemura K; Lee KM; Kawabata M; Fujisawa M; Nibu K; Shirakawa T
Br J Cancer; 2011 Jul; 105(3):393-402. PubMed ID: 21750550
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells.
Takahashi H; Li A; Dawson DW; Hines OJ; Reber HA; Eibl G
Pancreas; 2011 Apr; 40(3):453-9. PubMed ID: 21343834
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
Qin J; Yuan J; Li L; Liu H; Qin R; Qin W; Chen B; Wang H; Wu K
Biomed Pharmacother; 2009 Mar; 63(3):241-8. PubMed ID: 18617357
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
18. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.
Zhao S; Cai J; Bian H; Gui L; Zhao F
Cancer Invest; 2009 Jul; 27(6):636-40. PubMed ID: 19387877
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Grösch S; Maier TJ; Schiffmann S; Geisslinger G
J Natl Cancer Inst; 2006 Jun; 98(11):736-47. PubMed ID: 16757698
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
